Global Pcr Based Infectious Diseases Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 4,737,570.00 Thousand |
 Taille du marché (année de prévision) |
USD 7,720,895.13 Thousand |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial des maladies infectieuses basées sur la PCR, par type de test (test PCR pour la tuberculose, test PCR pour l'hépatite, test PCR pour le virus de l'immunodéficience humaine (VIH), test PCR pour la grippe, test PCR pour le virus du papillome humain (HPV), test PCT pour la gonorrhée, test PCR pour la salmonellose, test PCR pour le rotavirus, test PCR pour Bordetella, test PCR pour H. Pylori, test PCR pour le norovirus, test PCR pour le SRAS (COVID-19), test PCR pour Enterococcus, test PCR pour Chlamydia Trachomatis génital, test PCR pour C. Difficile (Clostridium Difficile), test PCR pour les entérobactéries résistantes aux carbapénèmes (CRE), test PCR pour Mycoplasma Genitalium (MG), test PCR pour Staphylococcus Aureus résistant à la méthicilline (SARM) et autres tests PCR), infection (infection virale, infection des voies respiratoires, infection sexuellement transmissible, infections nosocomiales et Autres infections, agents pathogènes (viraux, bactériens, fongiques, protozoaires et autres), technologie PCR (RT PCR, PCR multiplex et autres), type de patient (gériatrique, pédiatrique et adulte), tests (tests en laboratoire et tests au point de service), utilisateur final (centres de diagnostic, hôpitaux, instituts universitaires et de recherche, centres de santé communautaires, cliniques, soins de santé à domicile et autres) – Tendances et prévisions du secteur jusqu'en 2031.
Analyse et taille du marché des maladies infectieuses basées sur la PCR
Le marché mondial des maladies infectieuses basées sur la PCR est stimulé par l'incidence croissante des maladies infectieuses dans le monde, notamment les infections respiratoires, les infections sexuellement transmissibles , les infections gastro-intestinales et les maladies à transmission vectorielle, ce qui constitue un moteur important de la croissance du marché. En outre, l'augmentation de la demande de méthodes de diagnostic rapides et précises propulse davantage la croissance du marché. Cependant, le manque d'électricité fiable, de personnel qualifié et d'installations de laboratoire peut entraver l'adoption généralisée des tests basés sur la PCR, ce qui freine la croissance du marché.
Data Bridge Market Research analyse que le marché mondial des maladies infectieuses basées sur la PCR devrait atteindre 7 720 895,13 milliers USD d'ici 2031, contre 4 737 570,00 milliers USD en 2023, avec un TCAC de 6,6 % au cours de la période de prévision de 2024 à 2031.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (Personnalisable 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains, volume en unités, prix de vente moyen en dollars américains |
|
Segments couverts |
Type de test (test PCR pour la tuberculose, test PCR pour l'hépatite, test PCR pour le virus de l'immunodéficience humaine (VIH), test PCR pour la grippe, test PCR pour le virus du papillome humain (VPH), test PCR pour la gonorrhée, test PCR pour la salmonellose, test PCR pour le rotavirus, test PCR pour la Bordetella, test PCR pour H. Pylori, test PCR pour le norovirus, test PCR pour le SRAS (COVID-19), test PCR pour l'entérocoque, test PCR pour la Chlamydia Trachomatis génitale, test PCR pour C. Difficile (Clostridium Difficile), test PCR pour les entérobactéries résistantes aux carbapénèmes (CRE), test PCR pour Mycoplasma Genitalium (MG), test PCR pour Staphylococcus Aureus résistant à la méthicilline (SARM) et autres tests PCR), infection (infection virale, infection des voies respiratoires, infection sexuellement transmissible, infections nosocomiales et autres infections), agent pathogène (viral, Bactéries, champignons, protozoaires et autres), technologie PCR (RT PCR, PCR multiplex et autres), type de patient (gériatrique, pédiatrique et adulte), tests (tests en laboratoire et tests au point de service), utilisateur final (centres de diagnostic, hôpitaux, instituts universitaires et de recherche, centres de santé communautaires, cliniques, soins de santé à domicile et autres) |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, Royaume-Uni, Italie, France, Espagne, Russie, Suisse, Turquie, Belgique, Pays-Bas, Hongrie, Reste de l'Europe, Japon, Chine, Corée du Sud, Inde, Singapour, Thaïlande, Indonésie, Malaisie, Philippines, Australie, Reste de l'Asie-Pacifique, Brésil, Argentine, Reste de l'Amérique du Sud, Afrique du Sud, Égypte, Arabie saoudite, Émirats arabes unis, Israël et Reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center et LalPathLabs, entre autres |
Définition du marché
Le marché mondial des maladies infectieuses basées sur la PCR englobe un écosystème dynamique de produits et de services visant à détecter et à gérer les agents pathogènes infectieux grâce à l'application de la technologie de réaction en chaîne par polymérase (PCR). Ce marché comprend une gamme diversifiée de tests PCR, d'instruments, de réactifs et de solutions logicielles adaptés à l'identification et à la caractérisation de divers agents infectieux, notamment les virus, les bactéries, les champignons et les parasites. Les tests et kits PCR sont développés pour des agents pathogènes spécifiques, traitant un large éventail de maladies infectieuses telles que les infections respiratoires, les maladies sexuellement transmissibles, les maladies gastro-intestinales et les menaces infectieuses émergentes. Les instruments PCR, notamment les thermocycleurs et les systèmes PCR en temps réel, facilitent l'amplification et la détection des cibles d'acide nucléique dans les échantillons cliniques, tandis que les réactifs et les consommables soutiennent le flux de travail du laboratoire avec des composants essentiels pour les réactions PCR. De plus, les logiciels et les outils bioinformatiques aident à l'analyse des données, à l'interprétation et à la création de rapports sur les résultats des tests PCR, améliorant ainsi la précision et l'efficacité du diagnostic.
Dynamique du marché mondial des maladies infectieuses basées sur la PCR
Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
- Accroître les activités de recherche basées sur la PCR
La PCR est devenue une méthode clé dans le domaine du diagnostic et de la recherche sur les maladies infectieuses en raison de sa sensibilité, de sa spécificité et de son efficacité inégalées dans la détection et l'amplification des acides nucléiques. Les progrès continus des technologies PCR, associés à une meilleure compréhension de la composition génétique des agents pathogènes, ont permis la création de tests de diagnostic extrêmement précis et rapides. Les améliorations continues de la technologie PCR, telles que la PCR numérique et en temps réel, ont augmenté l'efficacité et la rapidité du diagnostic des maladies infectieuses. Ces développements permettent d'identifier les agents pathogènes plus rapidement et plus précisément, ce qui permet une intervention et un traitement rapides. L'essor des tests au point de service, qui augmente l'accès aux diagnostics dans divers contextes de soins de santé, est également facilité par l'amélioration continue des techniques PCR.
- Augmentation des cas de maladies infectieuses
La mondialisation, l’urbanisation et la dégradation de l’environnement sont quelques-unes des causes de l’augmentation de la fréquence des infections à l’échelle mondiale, ce qui rend indispensables des traitements diagnostiques, thérapeutiques et préventifs efficaces. La santé publique reste gravement menacée par les maladies infectieuses , dont la lutte est rendue plus difficile par l’apparition de nouveaux agents pathogènes et la réapparition de maladies jusque-là sous contrôle.
Opportunités
- Surveillance des maladies pour la détection précoce et le suivi des maladies infectieuses
La capacité des tests basés sur la PCR à offrir un outil robuste pour la surveillance continue des maladies représente une opportunité significative de croissance du marché. Ces tests, caractérisés par une sensibilité et une spécificité élevées, permettent une détection précoce et une surveillance continue des maladies infectieuses au sein des populations. La nature en temps réel de la PCR permet l'identification rapide des agents pathogènes, facilitant des mesures de réponse rapides et des stratégies de confinement efficaces.
Cette approche proactive est essentielle pour prévenir la propagation des maladies infectieuses et atténuer leur impact sur la santé publique. L'opportunité réside donc dans la capacité du marché à contribuer à la santé mondiale en fournissant des outils avancés de surveillance des maladies, permettant des interventions précoces et, en fin de compte, améliorant les résultats des soins de santé.
- Innovations croissantes dans la technologie PCR
Les innovations en cours dans la technologie PCR, notamment les progrès réalisés dans les tests PCR en temps réel et PCR multiplex, offrent une opportunité substantielle de croissance du marché. Ces avancées technologiques améliorent considérablement les capacités de test, offrant des solutions de diagnostic plus efficaces, rentables et complètes. La PCR en temps réel permet l'amplification et la quantification simultanées des acides nucléiques, fournissant des résultats rapides et précis. Parallèlement, les tests PCR multiplex permettent la détection de plusieurs cibles en une seule réaction, contribuant ainsi à une analyse plus approfondie des agents infectieux. Ces avancées améliorent non seulement la rapidité et la précision des diagnostics, mais améliorent également la rentabilité en consolidant plusieurs tests en un seul processus.
Contraintes/Défis
- Coût élevé des services de test PCR
La PCR est une technique de diagnostic puissante et précise qui permet d'identifier avec précision les agents pathogènes. Cependant, le coût élevé des tests PCR est en partie dû à la technologie avancée et à la nécessité de certains outils, matériaux et personnel qualifié. L'accessibilité peut être limitée par le coût de mise en œuvre et de maintenance des diagnostics basés sur la PCR, en particulier dans les zones où les ressources et les budgets de santé sont limités. Le diagnostic et le confinement des maladies infectieuses peuvent être retardés en raison du coût élevé des tests PCR, ce qui peut entraver les opérations de test à grande échelle.
D’autres facteurs contribuent au coût élevé des tests PCR. Tout d’abord, l’utilisation de la technologie elle-même nécessite des réactifs spécialisés coûteux et des équipements sophistiqués. L’investissement initial requis par les laboratoires pour établir des capacités PCR est amplifié par la nécessité d’instruments de précision tels que des thermocycleurs et des machines d’extraction d’acides nucléiques.
- Préoccupations relatives à la sécurité et à la confidentialité des données
La dépendance croissante aux plateformes numériques pour la communication et l’analyse des résultats des tests PCR pose un défi à la croissance du marché : la sécurité des données et les problèmes de confidentialité. Assurer la confidentialité et le traitement sécurisé des données de santé sensibles devient primordial à mesure que l’intégration des technologies numériques devient plus répandue dans le processus de test. Les vulnérabilités potentielles en matière de sécurité des données suscitent des appréhensions quant aux accès non autorisés, aux violations et à l’utilisation abusive des informations de santé personnelles. Il est essentiel de répondre à ces préoccupations non seulement pour se conformer aux réglementations strictes en matière de protection des données, mais aussi pour maintenir la confiance du public dans le processus de test. Une violation de la sécurité des données pourrait saper la confiance dans l’exactitude et la fiabilité des tests de maladies infectieuses basés sur la PCR, ce qui aurait un impact à la fois sur les individus et sur les initiatives de santé publique plus larges. Par conséquent, à mesure que le marché continue d’évoluer et d’adopter la numérisation, il doit donner la priorité à des mesures de protection des données robustes et à des protocoles de confidentialité transparents pour atténuer ces défis et maintenir la confiance du public qu’il sert.
Développements récents
- En septembre 2023, le programme de dépistage primaire du virus du papillome humain (HPV) a été lancé par pathlab. Le test HPV peut être effectué à l'aide de l'échantillon de cytologie en milieu liquide (LBC) existant (SurePath) ou à l'aide d'un écouvillon vaginal auto-collecté ou prélevé par un clinicien. Ce programme a amélioré les capacités de diagnostic en offrant une flexibilité dans la réalisation des tests HPV
- En août 2022, MicroGen Diagnostics a étendu ses activités dans le domaine de la détection ciblée des infections orthopédiques et urologiques par séquençage, suite à l'acquisition de nouveaux contrats et au lancement d'études de résultats. Cette décision stratégique a non seulement élargi l'offre de services de l'entreprise, mais a également ouvert des perspectives d'augmentation des revenus grâce à de nouveaux contrats
- En juin 2021, MicroGen Diagnostics a élargi ses compétences et ses capacités en matière de recherche primaire non clinique grâce à l'acquisition de son laboratoire partenaire, RTL Genomics. Cette décision stratégique a permis à l'entreprise d'élargir son champ d'activités de recherche, d'explorer de nouvelles voies de recherche scientifique et de potentiellement conduire à des découvertes révolutionnaires
Portée du marché mondial des maladies infectieuses basées sur la PCR
Le marché mondial des maladies infectieuses basées sur la PCR est segmenté en sept segments notables basés sur le type de test, l'infection, l'agent pathogène, la technologie PCR, le type de patient, les tests et l'utilisateur final. La croissance parmi ces segments vous aidera à analyser les principaux segments de croissance des industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Type de test
- Test PCR de dépistage de la tuberculose
- Test PCR pour l'hépatite
- Test PCR du virus de l'immunodéficience humaine (VIH)
- Test PCR de la grippe
- Test PCR pour le virus du papillome humain (HPV)
- Test PCT pour la gonorrhée
- Test PCR de salmonellose
- Test PCR pour le rotavirus
- Test PCR pour la détection de Bordetella
- Test PCR pour H. Pylori
- Test PCR pour le norovirus
- Test PCR pour le SRAS (COVID-19)
- Test PCR pour entérocoques
- Test PCR génital pour Chlamydia Trachomatis
- Test PCR pour C.difficile (Clostridium difficile)
- Test PCR pour les entérobactéries résistantes aux carbapénèmes (CRE)
- Test PCR pour Mycoplasma Genitalium (MG)
- Test PCR de détection du Staphylococcus aureus résistant à la méthicilline (SARM)
- Autre test PCR
Sur la base du type de test, le marché est segmenté en test PCR de la tuberculose, test PCR de l'hépatite, test PCR du virus de l'immunodéficience humaine (VIH), test PCR de la grippe, test PCR du virus du papillome humain (HPV), test PCT de la gonorrhée, test PCR de la salmonellose, test PCR du rotavirus, test PCR de Bordetella, test PCR de H. Pylori, test PCR du norovirus, test PCR du SRAS (COVID-19), test PCR d'entérocoque, test PCR génital de Chlamydia trachomatis, test PCR de C. Difficile (Clostridium Difficile), test PCR d'entérobactéries résistantes aux carbapénèmes (Cre), test PCR de Mycoplasma Genitalium (Mg), test PCR de Staphylococcus aureus résistant à la méthicilline (Mrsa) et autres tests PCR.
Infection
- Infection virale
- Infection des voies respiratoires
- Infection sexuellement transmissible
- Infections contractées à l'hôpital
- Autres infections
Sur la base de l’infection, le marché est segmenté en infection virale, infection des voies respiratoires, infection sexuellement transmissible, infections nosocomiales et autres infections.
Agent pathogène
- Viral
- Bactérien
- Fongique
- Protozoaires
- Autres
Sur la base de l'agent pathogène, le marché est segmenté en virus, bactéries, champignons, protozoaires et autres.
Technologie PCR
- RT-PCR
- PCR multiplexée
- Autres
Sur la base de la technologie PCR, le marché est segmenté en RT PCR, PCR multiplex et autres.
Type de patient
- Gériatrie
- Pédiatrique
- Adultes
En fonction du type de patient, le marché est segmenté en gériatrie, pédiatrie et adultes.
Essai
- Tests en laboratoire
- Tests au point de service
Sur la base des tests, le marché est segmenté en tests en laboratoire et en tests au point de service.
Utilisateur final
- Centres de diagnostic
- Hôpital
- Instituts universitaires et de recherche
- Centres de santé communautaires
- Cliniques
- Soins à domicile
- Autres
Sur la base de l'utilisateur final, le marché est segmenté en centres de diagnostic, hôpitaux, instituts universitaires et de recherche, centres de santé communautaires, cliniques, soins de santé à domicile et autres.
Analyse/perspectives régionales du marché mondial des maladies infectieuses basées sur la PCR
Le marché mondial des maladies infectieuses basées sur la PCR est segmenté en sept segments notables basés sur le type de test, l’infection, l’agent pathogène, la technologie PCR, le type de patient, les tests et l’utilisateur final.
Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada, le Mexique, l'Allemagne, le Royaume-Uni, l'Italie, la France, l'Espagne, la Russie, la Suisse, la Turquie, la Belgique, les Pays-Bas, la Hongrie, le reste de l'Europe, le Japon, la Chine, la Corée du Sud, l'Inde, Singapour, la Thaïlande, l'Indonésie, la Malaisie, les Philippines, l'Australie, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Égypte, l'Arabie saoudite, les Émirats arabes unis, Israël et le reste du Moyen-Orient et de l'Afrique.
Français La région Amérique du Nord devrait dominer le marché en raison de la présence d'infrastructures de soins de santé avancées, de l'innovation technologique, en particulier dans le domaine de la biotechnologie et du diagnostic moléculaire, et de la forte demande de diagnostics. Les États-Unis devraient dominer la région Amérique du Nord en raison de la présence d'infrastructures de soins de santé avancées, de l'innovation technologique, en particulier dans le domaine de la biotechnologie et du diagnostic moléculaire, et de la forte demande de diagnostics. L'Allemagne devrait dominer la région Europe en raison de sa forte présence sur les marchés internationaux, de ses vastes réseaux de distribution et de ses canaux de vente et de l'importance accordée à la recherche et au développement dans le secteur des sciences de la vie. La Chine devrait dominer la région Asie-Pacifique en raison de sa forte population, de sa forte charge de morbidité, de sa croissance économique rapide et de l'expansion des soins de santé.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et mondiales, l'impact des tarifs mondiaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du marché mondial des maladies infectieuses basées sur la PCR
Le paysage concurrentiel du marché mondial des maladies infectieuses basées sur la PCR fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché.
Certains des principaux acteurs du marché opérant sur le marché mondial des maladies infectieuses basées sur la PCR sont DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center, LalPathLabs et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES
5.1.2 RISING CASES OF INFECTIOUS DISEASES
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS
5.2 RESTRAINTS
5.2.1 HIGH COST OF PCR TEST SERVICES
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS
5.3 OPPORTUNITIES
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS
5.4 CHALLENGES
5.4.1 DATA SECURITY AND PRIVACY CONCERNS
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE
6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 TUBERCULOSIS PCR TEST
6.3 HEPATITIS PCR TEST
6.3.1 HEPATITIS C PCR TEST
6.3.2 HEPATITIS B PCR TEST
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST
6.5 INFLUENZA PCR TEST
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST
6.8 GONORRHEA PCR TEST
6.9 SALMONELLOSIS PCR TEST
6.1 ROTAVIRUS PCR TEST
6.11 BORDETELLA PCR TEST
6.12 H. PYLORI PCR TEST
6.13 SARS (COVID-19) PCR TEST
6.14 NOROVIRUS PCR TEST
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST
6.17 ENTEROCOCCUS PCR TEST
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST
6.2 OTHERS PCR TEST
7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION
7.1 OVERVIEW
7.2 VIRAL INFECTION
7.2.1 SARS (COVID-19) INFECTION
7.2.2 ROTAVIRUS INFECTION
7.2.3 NOROVIRUS INFECTION
7.2.4 OTHERS
7.3 RESPIRATORY TRACT INFECTION
7.3.1 INFLUENZA
7.3.2 TUBERCULOSIS
7.3.3 BORDETELLA
7.4 SEXUALLY TRANSMITTED INFECTION
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION
7.4.2 GONORRHEA
7.4.3 HEAPTITIS
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
7.4.5 HUMAN PAPILLOMAVIRUS (HPV)
7.4.6 MYCOPLASMA GENITALIUM (MG)
7.4.7 OTHERS
7.5 HOSPITAL ACQUIRED INFECTIONS
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE)
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE)
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
7.5.4 OTHERS
7.6 OTHER INFECTIONS
7.6.1 SALMONELLOSIS
7.6.2 H. PYLORI
7.6.3 ENTEROCOCCUS INFECTIONS
7.6.4 OTHERS
8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN
8.1 OVERVIEW
8.2 VIRAL
8.3 BACTERIAL
8.4 FUNGAL
8.5 PROTOZOA
8.6 OTHERS
9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY
9.1 OVERVIEW
9.2 RT PCR
9.3 MULTIPLEX PCR
9.4 OTHERS
10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 GERIATRIC
10.3 PEDIATRIC
10.4 ADULTS
11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING
11.1 OVERVIEW
11.2 LABORATORY BASED TESTING
11.3 POINT OF CARE TESTING
12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER
12.1 OVERVIEW
12.2 DIAGNOSTIC CENTERS
12.3 HOSPITAL
12.4 CLINICS
12.5 COMMUNITY HEALTH CENTERS
12.6 ACADEMIC AND RESEARCH INSTITUTES
12.7 HOME HEALTHCARE
12.8 OTHERS
13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 RUSSIA
13.3.6 SPAIN
13.3.7 TURKEY
13.3.8 NETHERLANDS
13.3.9 SWITZERLAND
13.3.10 BELGIUM
13.3.11 HUNGARY
13.3.12 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.2 AUSTRALIA
13.4.3 JAPAN
13.4.4 INDIA
13.4.5 SOUTH KOREA
13.4.6 SINGAPORE
13.4.7 MALAYISA
13.4.8 THAILAND
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 U.A.E.
13.6.3 SAUDI ARABIA
13.6.4 EGYPT
13.6.5 ISRAEL
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MICROGEN DIAGNOSTICS
16.1.1 COMPANY SNAPSHOT
16.1.2 SERVICE PORTFOLIO
16.1.3 RECENT DEVELOPMENTS
16.2 MAX LAB
16.2.1 COMPANY SNAPSHOT
16.2.2 SERVICE PORTFOLIO
16.3 DNA LABS INDIA
16.3.1 COMPANY SNAPSHOT
16.3.2 SERVICE PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 SERVICE PORTFOLIO
16.4.3 RECENT DEVELOPMENT
16.5 LALPATHLABS
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 AZOVA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 CLAREWELL CLINICS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT DESCRIPTION
16.7.3 RECENT DEVELOPMENTS
16.8 DRSAFEHANDS
16.8.1 COMPANY SNAPSHOT
16.8.2 SERVICE PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ONE LIFE HOME HEALTH CARE CENTER
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT DESCRIPTION
16.9.3 RECENT DEVELOPMENTS
16.1 PATHLAB
16.10.1 COMPANY SNAPSHOT
16.10.2 SERVICE PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 THE WASHINGTON TRAVEL CLINIC
16.11.1 COMPANY SNAPSHOT
16.11.2 SERVICE PORTFOLIO
16.11.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 4 GLOBAL TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 8 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 9 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 35 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 38 GLOBAL VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 GLOBAL BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 GLOBAL FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 GLOBAL PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 44 GLOBAL RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 GLOBAL MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 GLOBAL GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 GLOBAL PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 GLOBAL ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 52 GLOBAL LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 GLOBAL POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 54 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 55 GLOBAL DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 GLOBAL HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 GLOBAL CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 58 GLOBAL COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 GLOBAL HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 62 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 66 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 67 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 69 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 70 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 71 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 72 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 77 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 78 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 80 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 83 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 84 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 86 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 87 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 90 U.S. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 91 U.S. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 95 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 100 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 101 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 102 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 103 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 104 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 114 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 115 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 117 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 118 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 120 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 121 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 122 MEXICO VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 123 MEXICO RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 124 MEXICO SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 125 MEXICO HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 126 MEXICO OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 127 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 128 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 129 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 131 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 133 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 135 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 136 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 138 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 139 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 140 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 141 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 142 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 143 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 144 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 145 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 146 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 147 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 149 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 150 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 152 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 153 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 155 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 156 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 157 GERMANY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 158 GERMANY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 159 GERMANY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 160 GERMANY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 161 GERMANY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 162 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 163 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 164 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 166 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 167 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 169 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 170 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 172 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 173 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 174 FRANCE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 175 FRANCE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 176 FRANCE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 177 FRANCE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 178 FRANCE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 179 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 184 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 186 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 187 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 189 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 190 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 191 U.K. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 192 U.K. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 193 U.K. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 194 U.K. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 195 U.K. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 196 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 197 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 198 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 200 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 201 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 203 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 204 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 206 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 207 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 208 ITALY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 209 ITALY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 210 ITALY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 211 ITALY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 212 ITALY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 213 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 214 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 215 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 217 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 218 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 220 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 221 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 223 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 224 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 225 RUSSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 226 RUSSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 227 RUSSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 228 RUSSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 229 RUSSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 230 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 231 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 232 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 234 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 235 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 237 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 238 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 240 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 241 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 242 SPAIN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 243 SPAIN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 244 SPAIN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 245 SPAIN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 246 SPAIN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 247 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 248 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 249 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 251 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 252 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 254 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 255 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 257 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 258 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 266 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 268 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 271 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 272 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 274 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 275 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 276 NETHERLANDS VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 277 NETHERLANDS RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 278 NETHERLANDS SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 279 NETHERLANDS HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 280 NETHERLANDS OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 281 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 282 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 283 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 285 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 286 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 288 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 289 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 291 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 292 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 293 SWITZERLAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 294 SWITZERLAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 295 SWITZERLAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 296 SWITZERLAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 297 SWITZERLAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 298 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 299 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 300 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 302 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 305 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 306 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 308 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 309 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 311 BELGIUM RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 319 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 320 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 322 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 323 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 325 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 326 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 327 HUNGARY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 328 HUNGARY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 329 HUNGARY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 330 HUNGARY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 331 HUNGARY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 332 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 333 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 334 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 336 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 337 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 338 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 339 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 340 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 341 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 342 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 343 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 344 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 346 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 347 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 348 ASIA-PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 349 ASIA-PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 350 ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 351 ASIA-PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 352 ASIA-PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 353 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 354 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 355 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 357 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 358 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 360 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 361 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 362 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 363 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 364 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 365 CHINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 366 CHINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 367 CHINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 368 CHINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 369 CHINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 370 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 371 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 372 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 374 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 375 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 377 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 378 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 380 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 381 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 382 AUSTRALIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 383 AUSTRALIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 384 AUSTRALIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 385 AUSTRALIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 386 AUSTRALIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 387 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 388 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 389 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 390 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 391 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 392 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 393 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 394 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 395 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 396 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 397 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 398 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 399 JAPAN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 400 JAPAN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 401 JAPAN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 402 JAPAN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 403 JAPAN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 404 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 405 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 406 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 408 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 409 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 410 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 411 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 412 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 413 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 414 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 415 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 416 INDIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 417 INDIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 418 INDIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 419 INDIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 420 INDIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 421 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 422 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 423 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 424 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 425 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 426 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 427 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 428 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 429 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 430 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 431 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 432 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 433 SOUTH KOREA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 434 SOUTH KOREA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 435 SOUTH KOREA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 436 SOUTH KOREA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 437 SOUTH KOREA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 438 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 439 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 440 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 441 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 442 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 443 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 444 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 445 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 446 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 448 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 449 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 450 SINGAPORE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 451 SINGAPORE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 452 SINGAPORE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 453 SINGAPORE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 454 SINGAPORE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 455 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 456 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 457 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 458 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 459 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 460 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 461 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 462 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 463 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 464 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 465 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 466 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 467 MALAYSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 468 MALAYSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 469 MALAYSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 470 MALAYSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 471 MALAYSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 472 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 473 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 474 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 475 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 476 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 477 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 479 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 480 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 481 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 482 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 483 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 484 THAILAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 485 THAILAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 486 THAILAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 487 THAILAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 488 THAILAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 489 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 490 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 491 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 492 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 493 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 494 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 495 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 496 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 497 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 499 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 500 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 501 INDONESIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 502 INDONESIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 503 INDONESIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 504 INDONESIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 505 INDONESIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 506 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 507 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 508 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 509 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 510 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 511 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 512 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 513 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 514 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 515 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 516 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 517 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 518 PHILIPPINES VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 519 PHILIPPINES RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 520 PHILIPPINES SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 521 PHILIPPINES HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 522 PHILIPPINES OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 523 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 524 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 525 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 526 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 527 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 528 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 529 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 530 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 531 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 532 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 533 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 534 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 535 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 536 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 537 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 538 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 539 SOUTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 540 SOUTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 541 SOUTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 542 SOUTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 543 SOUTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 544 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 545 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 546 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 548 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 549 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 550 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 551 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 552 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 553 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 554 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 555 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 556 BRAZIL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 557 BRAZIL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 558 BRAZIL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 559 BRAZIL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 560 BRAZIL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 561 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 562 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 563 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 564 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 565 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 566 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 567 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 568 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 569 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 570 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 571 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 572 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 573 ARGENTINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 574 ARGENTINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 575 ARGENTINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 576 ARGENTINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 577 ARGENTINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 578 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 579 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 580 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 581 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 582 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 583 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 584 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 585 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 586 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 587 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 588 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 589 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 590 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 592 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 593 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 594 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 595 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 596 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 597 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 598 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 599 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 600 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 601 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 602 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 603 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 604 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 605 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 606 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 607 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 608 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 609 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 610 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 611 SOUTH AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 612 SOUTH AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 613 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 614 SOUTH AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 615 SOUTH AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 616 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 617 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 618 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 619 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 620 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 621 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 622 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 623 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 624 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 625 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 626 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 627 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 628 U.A.E. VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 629 U.A.E. RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 630 U.A.E. SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 631 U.A.E. HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 632 U.A.E. OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 633 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 634 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 635 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 636 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 637 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 638 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 640 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 641 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 642 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 643 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 644 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 645 SAUDI ARABIA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 646 SAUDI ARABIA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 647 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 648 SAUDI ARABIA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 649 SAUDI ARABIA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 650 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 651 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 652 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 654 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 655 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 656 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 657 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 658 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 660 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 661 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 662 EGYPT VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 663 EGYPT RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 664 EGYPT SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 665 EGYPT HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 666 EGYPT OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 667 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 668 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 669 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 670 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 671 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 672 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 673 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 674 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 675 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 676 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 677 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 678 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 679 ISRAEL VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 680 ISRAEL RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 681 ISRAEL SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 682 ISRAEL HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 683 ISRAEL OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 684 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 685 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 686 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 687 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 688 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 689 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 690 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 691 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
Liste des figures
FIGURE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PCR-BASED INFECTIOUS DISEASE MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET
FIGURE 16 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023
FIGURE 17 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023
FIGURE 21 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031)
FIGURE 23 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE
FIGURE 24 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023
FIGURE 25 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031)
FIGURE 27 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE
FIGURE 28 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023
FIGURE 29 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031)
FIGURE 31 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE
FIGURE 32 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023
FIGURE 33 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031)
FIGURE 35 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE
FIGURE 36 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023
FIGURE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND)
FIGURE 38 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031)
FIGURE 39 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE
FIGURE 40 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023
FIGURE 41 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 42 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031)
FIGURE 43 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023)
FIGURE 45 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
